NCT07021859Recruiting
Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide
Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide: A Randomized Clinical Trial
Source: ClinicalTrials.gov · Last updated 6 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Calcitonin gene-related peptide (CGRP) is a key neuropeptide in migraine pathophysiology and treatment. This study investigates whether CGRP administration can trigger aura in individuals with a diagnosis of migraine with aura.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 21 (estimated)
- First submitted
- 6 Jun 2025
- Start date
- 27 Jun 2025
- Primary completion date
- 1 Jun 2026
- Lead sponsor
- Danish Headache Center
- Diseases
- Migraine
- NCT number
- NCT07021859
What you commit to
- Study type: Interventional
- Planned participants: 21
- From 27 Jun 2025 to the primary completion date, 1 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Hypertension (systolic blood pressure of ≥150 mmHg and/or diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day
- Initiation, discontinuation, or change of dosing of prophylactic medications within 2 months prior to study inclusion
- Intake of acute medications (e.g. analgesics, triptans) within 48 hours of infusion start
Other illness
- Any history of a primary or secondary headache disorder other than migraine without aura, migraine with aura, chronic migraine, and episodic tension-type headache
- History or evidence of any other clinically significant disorder, condition, or disease (except for those outlined above) that, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion
- Cardiovascular disease of any kind, including cerebrovascular diseases
Other
- The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior
- Female subjects of childbearing potential with a positive pregnancy test during any study visit
- Hypotension (systolic blood pressure of ≤90 mmHg and/or diastolic blood pressure of ≤50 mmHg)
- Headache of any intensity within 48 hours of infusion start
- Aura within 48 hours of infusion start
Who the study is looking for
- Age 18 to 65 years of age upon entry into screening
- History of migraine with aura for ≥ 12 months according to the International Classification of Headache Disorders 3rd Edition (ICHD-3) criteria
- ≥ 1 monthly day with aura that meets criteria as aura on average across the three months before screening
- Provision of informed consent prior to initiation of any study-specific activities/procedures.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Rigshospitalet Glostrup Coordinator of this site? Confirm its status | Glostrup Municipality | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.